Celadon Pharmaceuticals

Celadon Pharmaceuticals is a vertically integrated UK biotech positioned as a leader in developing and manufacturing prescription cannabis-based medicines. The company's core assets include a 100,000 sq ft EU-GMP licensed cultivation and API production facility and a conditionally MHRA-approved Phase 2 clinical trial for chronic pain. Its strategy combines in-house R&D for IP generation with strategic investments, such as in Kingdom Therapeutics for autism spectrum disorder, aiming to build a robust data package for NHS reimbursement and commercial sales.

Vertically integrated EU-GMP platform featuring controlled indoor hydroponic cultivation with real-time sensor monitoring and a proprietary track-and-trace system for producing high-THC cannabinoid APIs.

Celadon competes with other licensed cannabis cultivators and biotechs developing cannabinoid drugs. Its key differentiators are its vertical integration, UK EU-GMP certification for high-THC API, and ownership of a government-approved Phase 2 pain trial, which is rare in the UK market.